Proactive Investors - Run By Investors For Investors

Avacta Group - Maximising Affimer's potential across therapeutics and diagnostic applications

Over the last year or so, management has delivered significant progress in bringing their Affimer platform into to the commercial stage, across both therapeutics and diagnostic applications.
Avacta Group - Maximising Affimer's potential across therapeutics and diagnostic applications

This (and the recent fundraise) leaves us confident that Avacta is on track to meet key development targets over the next 2-3 years. Their main therapeutic programs (in-house PD-L1/LAG3 bispecific Affimer and Affimer-drug conjugates co-developed with Tufts University) are on track to deliver key data points between 2019-2021.

Full report is available via Capital Network website
View full AVCT profile View Profile

Avacta Group PLC Timeline

Related Researches

no_picture_pai.jpg
March 28 2018

e-therapeutics reported results for the full year to Jan 31st 2018; business updates reflect good progress on the main research programs. Cash balance of £9.6mn was slightly higher than we expected, thanks to careful cost management.
 

no_picture_pai.jpg
July 30 2018

Avacta Group Plc (LON:AVACT) has recently finalised a co-development partnership with Boston-based Bach BioSciences, to exploit the potential of the Affimer platform for the development of a novel class of drug conjugates.

no_picture_pai.jpg
March 14 2018

OptiBiotix Health Plc (LON:OPTI) focuses on managing and treating widespread, chronic medical conditions, such as obesity and high cholesterol, through the modulation of the human microbiome.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use